MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
Submission of Matters to a Vote of Security Holders.
MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Submission of Matters to a Vote of Security Holders
MediciNova, Inc. (the “Company”) held its 2018 annual meeting of stockholders on June 7, 2018 (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April26, 2018.
At the close of business on April12, 2018, the record date of the Annual Meeting, the Company had 41,129,073 shares of common stock issued and outstanding. The holders of a total of 26,919,207 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting.
Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting
|
(a) |
To elect a Class II Director nominee named below to serve until the 2021 Annual Meeting of Stockholders. The named nominee was so elected, with the votes thereon at the Annual Meeting as follows: |
Final Voting Results
|
Nominee |
For |
Withheld |
Broker Non-Vote |
|
Yuichi Iwaki |
24,089,320 |
911,014 |
1,918,873 |
|
(b) |
To ratify the selection by the Audit Committee of the Company’s Board of Directors of BDO USA, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018 This proposal was approved, with the votes thereon at the Annual Meeting as follows: |
Final Voting Results
|
For |
Against |
Abstain |
Broker Non-Vote |
|
26,335,057 |
291,083 |
293,067 |
|
(c) |
To approve an amendment to the 2013 Equity Incentive Plan to increase the number of shares of Common Stock issuable under the Plan by 1,500,000 shares. This proposal was approved, with the votes thereon at the Annual Meeting as follows: |
Final Voting Results
|
For |
Against |
Abstain |
Broker Non-Vote |
|
23,300,255 |
1,248,552 |
451,527 |
1,918,873 |
About MEDICINOVA, INC. (NASDAQ:MNOV)
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.
